Ethanol does not significantly affect the bioavailability of almotriptan: An open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 9, 2006, Pages 443-448

  Cabarrocas, X ^a   Salva, M ^a   Pavesi, M ^a   Costa, J ^b  

^a Almirall Prodesfarma ^*  (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Almotriptan; Bioavailability; Ethanol; Pharmacokinetics; Tolerability

Indexed keywords

ALCOHOL; ALMOTRIPTAN;

ADULT; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MIGRAINE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VOLUNTEER;

EID: 33750706260     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44443     Document Type: Article

References (21)

1. Balbisi EA. Efficacy and safety of almotriptan malate for migraine. Am J Health Syst Pharm. 2002; 59: 2184-2193.
2. Blau JN. Migraine triggers: practice and theory. Pathol Biol (Paris). 1992; 40: 367-372.
3. Bou J, Domenech T, Puig J, Heredia A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000; 410: 33-41.
4. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia. 2001; 21: 804-812.
5. Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P. Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia. 1999; 19: 363.
6. Dahlöf CG, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache. 2002; 42: 99-113.
7. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther. 2000; 67: 498-503.
8. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001a; 21: 61-65.
9. Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol. 2001b; 41: 217-223.
10. Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJ, Burke MT, Azie NE. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001c; 51: 437-441.
11. Fleishaker JC, Herman BD, Carel BJ, Azie NE. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol. 2003; 43: 423-427.
12. García E, Cabarrocas X, Jansat JM. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT 1B/1D agonist, in healthy volunteers. Headache. 1988; 38: 381.
13. Gras J, Llupia J, Llenas J, Palacios JM. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics. Arzneimittelforschung. 2001; 51: 726-732.
14. Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 2002; 8: 217-234.
15. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-78.
16. Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol. 2002; 42: 1303-1310.
17. Keam S, Goa K, Figgitt D. Almotriptan: a review of its use in migraine. Headache. 2003; 43: 300-301.
18. McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005; 44: 237-246.
19. 1B/D agonist for the symptomatic treatment of migraine. Expert Rev Neurotherapeutics. 2001; 1: 20-27.
20. Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003; 31: 404-411.
21. Von S. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability. Am J Manag Care. 2002; 8: S74-79.